Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse effects and withdrawal, while emphasizing emerging nonsteroidal therapies as promising safer alternatives for personalized care.

An expert discusses the shift from reactive to proactive treatment of atopic dermatitis (AD), emphasizing personalized care and the growing role of advanced nonsteroidal topicals—such as PDE4 and JAK inhibitors—alongside updated guidelines aimed at improving clinician awareness and patient outcomes.

An expert discusses proactive management strategies for atopic dermatitis (AD), emphasizing daily gentle skin care, proper use of topical treatments, avoidance of outdated therapies such as routine antihistamines or steroids, and a shift toward personalized, flare-preventive care using newer therapeutic options.

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body surface area (BSA) estimation, and the Pruritus Numerical Rating Scale (NRS) to guide personalized treatment and improve symptom tracking in routine clinical care.

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar conditions, and the critical role of education and skin care in effective management, particularly in primary care settings.

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of collaboration between dermatology and primary care providers to improve patient outcomes.

Your daily dose of the clinical news you may have missed.

Infectious disease expert Amesh Adalja, MD, outlines the biggest vaccine policy shifts of 2025, including changes to COVID-19 and flu vaccine recommendations.

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.